These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 38685486)
1. Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial. Zhao Y; Li D; Zhuang J; Li Z; Xia Q; Li Z; Yu J; Wang J; Zhang Y; Li K; Xu S; Li S; Ma P; Cao Y; Liu C; Xu C; Liu Z; Wei J; Zhang C; Qiao L; Gao X; Hou Z; Liu C; Zheng R; Wang D; Liu Y Clin Transl Med; 2024 May; 14(5):e1674. PubMed ID: 38685486 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study. Li N; Li Z; Fu Q; Zhang B; Zhang J; Wan XB; Lu CM; Wang JB; Deng WY; Ma YJ; Bie LY; Wang MY; Li J; Xia QX; Wei C; Luo SX Int J Surg; 2024 Apr; 110(4):2071-2084. PubMed ID: 38320099 [TBL] [Abstract][Full Text] [Related]
3. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR). Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of camrelizumab combined with oxaliplatin and S-1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single-arm study. Zhong WJ; Lin JA; Wu CY; Wang J; Chen JX; Zheng H; Ye K Cancer Med; 2024 Feb; 13(3):e7006. PubMed ID: 38400680 [TBL] [Abstract][Full Text] [Related]
5. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258 [TBL] [Abstract][Full Text] [Related]
6. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial. Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Sah BK; Zhang B; Zhang H; Li J; Yuan F; Ma T; Shi M; Xu W; Zhu Z; Liu W; Yan C; Li C; Liu B; Yan M; Zhu Z Nat Commun; 2020 Nov; 11(1):6093. PubMed ID: 33257672 [TBL] [Abstract][Full Text] [Related]
8. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial. Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma. Shamseddine A; Zeidan YH; El Husseini Z; Kreidieh M; Al Darazi M; Turfa R; Kattan J; Khalifeh I; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Charafeddine M; Geara F Radiat Oncol; 2020 Oct; 15(1):233. PubMed ID: 33028346 [TBL] [Abstract][Full Text] [Related]
10. A comparative analysis on clinical efficacy of FOLFOX6 regimen and DCF regimen as neoadjuvant chemotherapy combined with radical gastrectomy in treating advanced gastric cancer. Tai Q; Shao H; Liu Y; Li E; Zhao R J BUON; 2019; 24(5):2006-2012. PubMed ID: 31786868 [TBL] [Abstract][Full Text] [Related]
11. A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. Bang YJ; Kang YK; Ng M; Chung HC; Wainberg ZA; Gendreau S; Chan WY; Xu N; Maslyar D; Meng R; Chau I; Ajani JA Eur J Cancer; 2019 Feb; 108():17-24. PubMed ID: 30592991 [TBL] [Abstract][Full Text] [Related]
12. PD-1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR/MSS colorectal cancer. Pei F; He W; Duan Y; Yao Q; Zhao Y; Fan X; Liu S; Chen H; He F; Liu T; Chen J; Zheng Y; Li H; Guo X; Shi L; Ling L; Chen Y; He J; Liu M; Huang M; Bai Y; Wang J; Huang M; Huang J Cancer Med; 2024 Jun; 13(12):e7224. PubMed ID: 38888366 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study). Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925 [TBL] [Abstract][Full Text] [Related]
14. Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol. Wu L; Yan H; Qin Y; Huang M; Wang T; Jin Q; Wei W BMJ Open; 2024 Feb; 14(2):e075696. PubMed ID: 38341203 [TBL] [Abstract][Full Text] [Related]
15. mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214). Hofheinz RD; Herrle F; Dechow T; von Weikersthal LF; Welslau M; Lettmaier S; Burkart C; Kubicka S; Kochen L; Merx K; Krause K; Ebert M; Rödel C; Fokas E; Ghadimi M; Reissfelder C; Gaiser T ESMO Open; 2024 Sep; 9(9):103703. PubMed ID: 39260162 [TBL] [Abstract][Full Text] [Related]
16. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma. Shamseddine A; Zeidan YH; Kreidieh M; Khalifeh I; Turfa R; Kattan J; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Khoury C; El Husseini Z; Charafeddine M; Al Darazi M; Geara F BMC Cancer; 2020 Sep; 20(1):831. PubMed ID: 32873251 [TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358 [TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study. Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658 [TBL] [Abstract][Full Text] [Related]
19. Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. Ozdemir N; Abali H; Vural M; Yalcin S; Oksuzoglu B; Civelek B; Oguz D; Bostanci B; Yalcin B; Zengin N Cancer Chemother Pharmacol; 2014 Dec; 74(6):1139-47. PubMed ID: 25234436 [TBL] [Abstract][Full Text] [Related]
20. Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy. Yeh YS; Chen YT; Tsai HL; Huang CW; Ma CJ; Su WC; Huang CM; Huang MY; Hu HM; Lu CY; Wang JY Pathol Oncol Res; 2020 Apr; 26(2):1105-1116. PubMed ID: 31077069 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]